Session Title: Quick Fire Free Paper 1
Session Date/Time: Thursday 11/09/2014 | 08:00-10:00
Paper Time: 08:25
Venue: Boulevard D
First Author: : H.Al-Nashar EGYPT
Co Author(s): :
To evaluate the efficacy of topical alpha-2 agonist (brimonidine) in the treatment of diabetic maculopathy with mixed edema and ischemia
Patients are in the Zagazig University Hospitals, Zagazig, Sharkya, Egypt.
Twenty two eyes of twenty two patients are involved in this study. All eyes have mixed diabetic maculopathy as diagnosed by fluorescein angiography and spectral domain optical coherence tomography (SD-OCT) (Spectralis HRA-OCT; Heidelberg engineering, Heidelberg, Germany). They were treated by topical brimonidine twice daily for 3 months. Visual acuity, fluorescein angiography & OCT were done for all patients before the beginning of the treatment and every one month for 3 months later on to detect the change in ligMAR visual acuity and the changes in foveal avascular zone (FAZ) size and the macular thickness.
The mean logMAR visual acuity at the beginning of the treatment was 0.9±0.012 and improved to 0.7±0.1 after 3 months (P= 0.03). Size of FAZ was improved after the treatment. The mean central macular thickness was 425±125 µm and changed to 400±23 µm after 3 months (P=0.9).
Alpha 2 agonist (brimonidine) has a role in the treatment of mixed diabetic maculopathy